Connect with us
European Gaming Congress 2024

Fintech PR

New guide launched, “Better Conversations about Ethical Storytelling,” to help transform what stories we tell and how they are told




Over 100 NGOs and campaigners unite to revolutionise ethical storytelling in the development, humanitarian and philanthropic sectors.

LONDON, and NAIROBI, Kenya, Sept. 6, 2023 /PRNewswire/ — Consisting of six chapters and a series of videos, the guide was co-created with input from over 140 participants – including civil society and those with lived experience, and facilitated by M&C Saatchi World Services. Chapters cover making the business case for ethical storytelling, measuring impact, building trust and putting this into practice.

“The landscape is evolving to one that is more socially aware. Our audiences and our funders are evolving,” said Victor Mark-Onyegbu, Grants Lead at Africa No Filter.  One of the findings is that ethical storytelling is not simply a case of telling the same stories more ethically, but diversifying the kinds of stories we tell. Giving a platform to people with lived experience to share their opinions and solutions enhances decision-making, program effectiveness and builds trust.

For decades, some commentary has suggested that narratives have inadvertently perpetuated stereotypes painting communities as problems to be saved rather than as part of the solution. Levis Nderitu, from PATH, said that “As we all become more conscious of the need for power shifts, it has become important for organizations to update storytelling practices to keep up with industry norms”.

Chilande Kuloba-Warria, one of the authors, emphasized the need for community voices to be at the forefront of storytelling: “We have this African proverb that says until the lion learns how to write, every story will always glorify the hunter. That’s the spirit of the narrative I see needing to change, because too rarely do we see and hear the voices of the very same communities that we are looking to serve.”


“Instead of simply offering one-off guidance, this project takes a conversational approach which is intended to stimulate better conversations about ethical storytelling. Rather than present any one perspective as ‘right’, we make room for different perspectives, surface tricky judgments and invite the reader to reflect on the challenges,” said M&C Saatchi World Services Director of Strategy Andy Wright, whose agency led the facilitation of the project.

The toolkit was shaped by organizations such as Africa No Filter, BRAC, CARE and Grantmakers for Girls of Color. It was facilitated by M&C Saatchi World Services. This free guide and a full list of contributors is available here

Chapters authored by:

  • Chilande Kuloba-Warria Warande Advisory Centre
  • David Verga PATH
  • Levis Nderitu PATH
  • Shalini Moodley MetroGroup
  • Diah Dwiandani Ford Foundation
  • Denis Koech SHOFCO / Farm Input Promotions Africa
  • Denis Muwanguzi Mama Hope/ Budondo Intercultural Centre
  • Josefina Casati Grantmakers for Girls of Color
  • Sarah Jane Saltmarsh, BRAC

Contributions from the following:

  • Clare Spurrell, CARE
  • Victor Mark-Onyegbu, Africa No Filter
  • Gertrude Zoe Kabwaz, Yamba Malawi
  • Patience Musiwa-Mkandawire, Fount for Nations
  • Monica Nyiraguhabwa, Girl Up Initiative Uganda
  • Jennifer Mwikali Katiwa, Jitegemee Children
  • Chloe Namwase, Wezesha Impact
  • Raquel Thomas, Grantmakers for Girls of Color
  • Michel Lunanga, Doctors Without Borders/Lens on Life
  • Mardiyah Chamim, Development Dialogue Asia
  • Ari Trismana, WatchdoC Indonesia
  • Michelin Sallata, Barisan Pemuda Adat Nunsantara
  • Matthew and Tracy Angus Hammond, T2T Africa
  • Lamea Tanjin Tanha, TransEnd
  • Shakil Ahmed, Ridiculous Futures
  • Peter Torres Fremlin, Disability Debrief
  • Amy Frisch, SS+K (New York)
  • Jane Body, Mama Hope
  • Lydia BradleyMercyCorps
  • Eddy Zheng, New Breath Foundation
  • Kellie Ryan, International Rescue Committee
  • Anthony Ramos, Children’s Aid
  • Parul Sheth, Shaishav Children
  • Synoeun Nov, Empowering Youth in Cambodia
  • Raphaël Poutignat, Empowering Youth in Cambodia
  • Jessica Kirk-Bowman, Mercy Corps
  • Ana Maria Olarte, Mercy Corps
  • Jess Crombie, University of the Arts London
  • Heba Aly, The New Humanitarian
  • Joanna Colangelo, Razem Worldwide

View original content:

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024




STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting


The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision


The following files are available for download:

Invitation to presentation of EQT AB’s Q1 Announcement 2024,c3285895


EQT AB Group


View original content:

Continue Reading

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs



  • Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
  • Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
  • Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
    • Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
    • PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
  • Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
  • 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
  • CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”


Photo –

Cision View original content to download multimedia:

Continue Reading

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update




VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.


BioVaxys Technology Corp. (, a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit and connect with us on X and LinkedIn.


Signed “James Passin
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo –

Cision View original content:

Continue Reading